We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Breast cancer prevention by antihormones and other drugs: where do we stand?
Hematology/oncology Clinics of North America 2013 August
Breast cancer is the most common cancer in women worldwide. The selective estrogen-receptor (ER) modulators tamoxifen and raloxifene are approved by the Food and Drug Administration for the preventive therapy of breast cancer. Other drugs have shown promise but need further assessment. In the present review, we present an update of the chemoprevention of ER-positive breast cancer and discuss the potential role of metformin and aspirin, 2 drugs other than the specific "antihormones."
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app